UAlberta researcher Burim Ametaj's theory challenges 200 hundred years of science and his work may change the approach for treatment.

Dysparathyroidism, encompassing both hyperparathyroidism and hypoparathyroidism, significantly affects calcium and phosphate ...

Treatment with denosumab vs oral bisphosphonates was associated with increased risks for MACE and hypocalcemia in dialysis-dependent patients with osteoporosis.

BridgeBio Pharma (NASDAQ:BBIO) used its presentation at the 44th annual J.P. Morgan Healthcare Conference to highlight ...

Ethylene glycol poisoning occurs when someone ingests ethylene glycol. If ingested, it can cause significant morbidity and mortality.

Oct 29 (Reuters) - BridgeBio Pharma's (BBIO.O), opens new tab experimental drug for a rare genetic condition that causes low blood calcium met all the main and secondary goals in a late-stage study, ...

BridgeBio Pharma is having a banner week, with the Bay Area company’s encaleret acing a phase 3 trial just days after another late-stage rare disease win as its eyes an FDA review in 2026. In the ...

PALO ALTO, Calif., Oct. 29, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today ...

There’s no cure for hypoparathyroidism, but treatment options like calcium supplements, diuretics, and parathyroid hormone therapy can help regulate your calcium and phosphate levels.

This site contains product affiliate links. We may receive a commission if you make a purchase after clicking on one of these ...

Denosumab treatment for osteoporosis raises the risk for hypocalcemia, which worsens with advancing stages of chronic kidney disease (CKD), in those with CKD–Mineral and Bone Disorder (CKD-MBD) and in ...

The researchers found that with denosumab vs oral bisphosphonates, the risk for emergently treated hypocalcemia increased with worsening CKD stage. (HealthDay News) — For patients with chronic kidney ...